Magle Chemoswed Holding Reports Financial Results For First Half year 2022

Q2 2022 KEY INDICATORS

  • Net sales amounted to 35.4MSEK (33.5)
  • EBITDA equalled 7.7 MSEK (4.0)
  • Operating profit (EBIT) is 4.0 MSEK (1.2)
  • Profit after tax amounted to 3.8 MSEK (0.7)
  • Earnings per share SEK 0.4 (0.1) per share

 
JAN-JUNE 2022 KEY INDICATORS

  • Net sales amounted to 65.7 MSEK (64.0)
  • EBITDA equalled 14.2 MSEK (7.5)
  • Operating profit (EBIT) is 7.5 MSEK (2.0)
  • Profit after tax amounted to 6.7 MSEK (1.8)
  • Earnings per share SEK 0.6 (0.1) per share

 
RECENT BUSINESS ACCOMPLISHMENTS

  • Agreement with Malmö Stad for expansion of the Malmö manufacturing site
  • Post-market clinical study of SmartPAN started
  • Commercial manufacturing start-up of AXXO WOUNDGEL

“Our second quarter results show development as we see the benefit of increased sales of our DSM proprietary medical products, as well as continued strong demand from international pharma and biotech companies for our pharmaceutical development and manufacturing services. I am pleased to see that the increased focus on DSM products is a contributing factor to financial performance in the first half of 2022, as this underpins that our underlying growth strategy is continuing to pay off,” says Justin Pierce, CEO of Magle Group.